脑机概念股盘中急升，截至发稿，南京熊猫电子股份(00553)涨16.8%，报5.81港元；微创脑科学(02172) 涨8.81%，报15.68港元。 消息面上，工业和信息化部、国家发展改革委、教育部、国家卫生健康委、国务院国资委、中国科学 院、国家药监局发布关于推动脑机接口产业创新发展的实施意见。其中提出，发展辅助设备。研发辅助 生理信号设备，通过脑信号与肌电、眼电、心电、近红外等多模态信号的融合，提升交互控制和感知觉 评估的精准度。研发用于植入脑机接口的高精度手术机器人，突破亚微米级精度控制与动态调整技术， 提升区域精准实时成像与三维重建能力。 本文源自：智通财经网 开源证券表示，填补脑机接口医疗服务的价格空白，有望加快落地脑机接口落地运用。脑机接口下游应 用市场潜力大，全球脑机接口医疗应用市场规模有望在2030年达到400亿美元，2040年达到1450亿美 元。上海证券指出，脑机接口技术正从实验室快速走向商业化应用，中国市场迎来高速增长，存在较大 上升空间。 ...

Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創腦科學有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： ...

消息面上，据报道，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术标准。 周一公布的一段展示视频，首次演示了这项技术的进展。演示视频显示，一位渐冻症患者通过脑机设备 成功实现用意念控制iPad操作，并展现应用脑机接口使用"快捷指令"等操作。 另据央视新闻报道，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增 了100多项与医疗新技术相关的价格项目。其中，神经系统类立项指南统一设立"脑机接口置入费""脑机 接口适配费"等价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。湘财证券 认为，作为医疗领域前沿技术，脑机接口的应用将在患者检测、疾病康复、技能替代等方向逐步落地。 智通财经APP获悉，脑机概念股走高，截至发稿，南京熊猫电子股份(00553)涨4.93%，报5.11港元；微 创脑科学(02172)涨3.72%，报14.22港元。 ...

脑机概念股走高，截至发稿，南京熊猫（600775）电子股份(00553)涨4.93%，报5.11港元；微创脑科学 (02172)涨3.72%，报14.22港元。 另据央视新闻报道，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增 了100多项与医疗新技术相关的价格项目。其中，神经系统类立项指南统一设立"脑机接口置入费""脑机 接口适配费"等价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。湘财证券 认为，作为医疗领域前沿技术，脑机接口的应用将在患者检测、疾病康复、技能替代等方向逐步落地。 消息面上，据报道，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术标准。 周一公布的一段展示视频，首次演示了这项技术的进展。演示视频显示，一位渐冻症患者通过脑机设备 成功实现用意念控制iPad操作，并展现应用脑机接口使用"快捷指令"等操作。 ...

智通财经获悉，据央视新闻报道，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价 格机制，新增了100多项与医疗新技术相关的价格项目。其中，报道特别强调了对脑机接口技术进入临 床并收费的支持情况：神经系统类立项指南统一设立"脑机接口置入费""脑机接口适配费"等价格项目， 脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。 3月12日，国家医保局印发《神经系统类医疗服务价格项目立项指南(试行)》，其中专门为脑机接口新 技术单独立项，设立了"侵入式脑机接口置入费""侵入式脑机接口取出费""非侵入式脑机接口适配费"等 价格项目。 3月以来，湖北、浙江、江苏三省已纷纷公示脑机接口相关医疗服务价格项目：江苏省医疗保障局拟定 江苏省脑机接口相关医疗服务价格项目，非侵入式脑机接口适配费为966元/次，侵入式脑机接口置入费 为6600元/次，侵入式脑机接口取出费为3200元/次。浙江省医保局出台《关于公布脑机接口相关医疗服 务价格项目的通知》，其中侵入式脑机接口置入费6580元/次，侵入式脑机接口取出费3150元/次，非侵 入式脑机接口适配费966元/次。湖北省医保局发布脑机接口医疗服务价格，侵入式脑机接口 ...

New Stock Listings - Dingjia Precision listed on July 31, 2025, with an issue price of 11.16[1] - Shenkai Co., Ltd. has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] Market Alerts - Xizang Tourism reported severe abnormal fluctuations on July 31, 2025[1] - A total of 30 companies have announced abnormal fluctuations in their stock prices recently[2] Financial Data - The report includes links to detailed announcements for each stock, providing transparency and access to further information[1] - The document lists various companies with their respective stock codes and announcement dates, indicating active market engagement[1]

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 1.88%, with notable gains from constituent stocks such as MicroPort Medical (00853) up 8.63%, and Stone Pharmaceutical Group (01093) up 7.40% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 3.00%, marking its third consecutive increase, with a latest price of 1.34 HKD and a weekly cumulative increase of 8.89% [1] - The trading volume for the Hang Seng Biotechnology ETF was active, with a turnover of 34.45% and a transaction value of 161 million HKD, indicating strong market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, growing by 2 million shares over the past week, ranking in the top third among comparable funds [2] - The ETF has seen continuous net inflows over the last three days, with a peak single-day net inflow of 3.83 million HKD, totaling 8.73 million HKD in net inflows [2] Group 3 - Over the past year, the net value of the Hang Seng Biotechnology ETF has increased by 130.59%, ranking 3rd out of 122 QDII equity funds, placing it in the top 2.46% [3] - WuXi Biologics announced the construction of a modular biomanufacturing facility in Singapore, which is part of a strategic collaboration with Pharmadule Morimatsu [3] - The latest report from Zhongyin Securities suggests focusing on three main lines: 1) sectors with stable growth such as medical devices and pharmaceuticals, 2) the CXO sector and medical equipment expected to see a turnaround, and 3) innovative fields related to national medical insurance negotiations [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is highlighted as the only ETF tracking the Hang Seng Biotechnology Index to have received net inflows this year, with the lowest management fee of 0.15% per year among Hong Kong pharmaceutical ETFs [4]

Group 1 - The Hang Seng Index fell by 0.43%, down 109 points, while the Hang Seng Tech Index dropped by 1.57%. The morning trading volume in Hong Kong stocks was HKD 148.2 billion [1] - The Hang Seng Biotechnology Index rose by 1.77%, with notable gains from MicroPort Medical (00853) up 9.7%, MicroPort NeuroScience (02172) up over 8%, and Innovent Biologics (01801) up 4.85% [1] - WuXi AppTec (02359) increased by 2.24%, WuXi Biologics (02126) rose by 6.5%, and WuXi Biologics (02269) saw an increase of over 3% after announcing the construction of a modular biomanufacturing facility in Singapore [1] Group 2 - Mindray Medical-B (02160) surged by 8.8% as the company is expected to acquire and restructure the MicroPort cardiac rhythm management business, enhancing its product pipeline [2] - Insurance stocks continued to rise, with New China Life Insurance (01336) up 4.47% and China Life Insurance (02628) increasing by 1.5% [3] Group 3 - 361 Degrees (01361) rose by 6.5%, with the company showing steady revenue growth, and institutions expect strong revenue growth for the full year [4] - Dreamscape (01119) increased by 3.5% after signing a capitalization agreement with Playrix, bringing in a long-term strategic partner [5] Group 4 - GAC Group-B (01167) surged over 20% as a concerted action party increased its holdings by over 60,000 shares, raising its stake to 25.36% [6] - Semiconductor stocks collectively declined, with Hua Hong Semiconductor (01347) down 5.3%, SMIC (00981) down 3.9%, and ASMPT (00522) down 2.74% [6]

Market Overview - The Hang Seng Index fell by 0.43%, down 109 points, while the Hang Seng Tech Index decreased by 1.57%. The early trading volume in Hong Kong stocks was HKD 148.2 billion [1]. Biotechnology Sector - The Hang Seng Biotechnology Index rose by 1.77%. Notable gainers included MicroPort Medical (00853) up 9.7%, MicroPort NeuroTech (02172) up over 8%, and Innovent Biologics (01801) up 4.85% [1]. - WuXi AppTec (02359) increased by 2.24%, WuXi Biologics (02126) rose by 6.5%, and WuXi Biologics (02269) saw an increase of over 3% following the announcement of the construction of a modular biologics manufacturing facility in Singapore [1]. - Fosun Pharma (02196) gained over 5% after acquiring exclusive rights for the innovative Alzheimer's drug AR1001 [1]. - HeartCare Medical-B (02160) surged by 8.8% as the company is expected to acquire and restructure MicroPort's cardiac management business, enhancing its product pipeline [1]. Insurance Sector - Insurance stocks continued their upward trend, with New China Life Insurance (01336) rising by 4.47% to reach a new high, and China Life Insurance (02628) increasing by 1.5% [2]. Consumer Sector - 361 Degrees (01361) rose by 6.5%, with institutions expecting strong revenue growth for the full year [3]. - Dreamland (01119) increased by 3.5% after signing a capitalization agreement with Playrix, bringing in a strategic shareholder from the upstream development sector [4]. Semiconductor Sector - Gako Technology-B (01167) surged over 20% as a concerted action party increased its stake by over 60,000 shares, raising its total holding to 25.36% [5]. - Semiconductor stocks collectively declined, with Huahong Semiconductor (01347) down 5.3%, SMIC (00981) down 3.9%, and ASMPT (00522) down 2.74%. Nvidia's order for 300,000 H20 chips and Morgan Stanley's comments on the potential impact of the 520 unlock on local industry sentiment contributed to this decline [5].